公司概覽
業務類別 Biotechnology
業務概覽 Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
公司地址 500 Rutherford Avenue, Third Floor, Charlestown, MA, USA, 02129
電話號碼 +1 617 337-4680
傳真號碼 --
公司網頁 https://www.solidbio.com
員工數量 121
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. David Tyronne Howton Chief Operating Officer and Secretary 美元 513.42K 23/04/2026
Mr. Alexander G. Cumbo President, Chief Executive Officer and Director 美元 650.99K 23/04/2026
Mr. Kevin Tan Treasurer, Chief Financial Officer and Principal Accounting Officer -- 23/04/2026
Dr. Paul Herzich, PhD Chief Technology Officer -- 23/04/2026
Dr. Jessie Hanrahan, PhD Chief Regulatory and Preclinical Operations Officer -- 23/04/2026
Dr. Gabriel Brooks, M.D. Chief Medical Officer 美元 502.16K 23/04/2026
 
董事會成員
董事會 職務 更新日期
Mr. Ian F. Smith Executive Chairman of the Board 23/04/2026
Dr. Sukumar Nagendran, M.D. Independent Director 23/04/2026
Dr. Martin Freed, F.A.C.P.,M.D. Independent Director 23/04/2026
Mr. Alexander G. Cumbo President, Chief Executive Officer and Director 23/04/2026
Mr. Ilan Ganot Director 23/04/2026
Mr. Adam Stone Independent Director 23/04/2026
Ms. Lynne Sullivan Independent Director 23/04/2026
Dr. Georgia Keresty, M.P.H.,PhD Independent Director 23/04/2026
Dr. Clare Kahn, PhD Independent Director 23/04/2026
 
所屬ETF (更新日期: 07/11/2026 03:35)
代號 名稱 佔比% ▼ 持有日期
SCHBSchwab US Broad Market ETF™0.04%31/10/2026
VTWGVanguard Russell 2000 Growth ETF0.04%30/09/2026
BBCVirtus Biotech Clinical Trials ETF0.03%30/10/2026
VTWVVanguard Russell 2000 Value ETF0.03%30/09/2026
DFAUDimensional US Core Equity Market ETF0.02%30/10/2026
IWViShares Russell 3000 ETF0.02%30/10/2026
DFUSDimensional US Equity Market ETF0.02%30/10/2026
TMEDT. Rowe Price Health Care ETF0.02%31/10/2026
AVUSAvantis US Equity ETF0.01%30/10/2026
DCORDimensional US Core Equity 1 ETF0.01%24/09/2026
IBRNiShares Neuroscience and Healthcare ETF0.01%30/10/2026
IBBQInvesco Nasdaq Biotechnology ETF0.01%30/10/2026
RFLRInnovator U.S. Small Cp Mgd Flr ETF0.01%30/10/2026
DFSUDimensional US Sustainability Core 1 ETF0.01%30/10/2026
MSSMMorgan Stanley Pathway Sm-Md Cp Eq ETF0.01%31/10/2026
VTHRVanguard Russell 3000 ETF0.01%30/09/2026
BIBProShares Ultra Nasdaq Biotechnology0.004%30/10/2026
ITWOProShares Russell 2000 High Income ETF0.004%30/10/2026
URTYProShares UltraPro Russell20000.003%30/10/2026
DXUVDimensional US Vector Equity ETF0.002%24/09/2026
  1   2    3  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.